Grifols donates 140 Million international units of blood clotting factors to the World Federation of Hemophilia humanitarian aid program
Helping treat tens-of-thousands of patients in developing countries by renewing partnership with WFH, reaffirming commitment to improving patient's lives.
April 20, 2017
By Kelsea Koh
Grifols, S.A. announced that it will donate a minimum of 140 million international units (IU) of blood clotting factor medicines to the World Federation of Hemophilia (WFH) Humanitarian Aid Program over the next five years. This announcement is a continuation of the Company’s three-year commitment from 2014, bringing the total humanitarian aid commitment to more than 200M IU of Factor VIII over eight years. Grifols’ direct contribution to the WFH Humanitarian Aid Program builds on the Company’s participation in Project Recovery, which transforms previously unused cryoprecipitate from Canadian blood donors into medicines that treat hemophilia patients in developing countries.
For more than a decade Grifols has been a proud supporter of the WFH and its efforts to improve access to treatment of bleeding disorders around the world. The renewed partnership with WFH reaffirms Grifols’ commitment to the global hemophilia community accounting for the Company’s most significant contribution to the WFH Humanitarian Aid Program to date. According to the WFH, this donation of Factor VIII medicines will secure a projected average of 10,300 doses to treat approximately 6,000 patients per year in developing countries worldwide through 2021, where access to adequate treatment is often lacking or absent.
“Today, World Hemophilia Day represents ideal timing for Grifols to reaffirm our long-standing commitment to bleeding disorders and the hemophilia community,” said Victor Grifols Roura, president of Grifols. “Our philosophy aligns fully with the mission of WFH, sharing a clear passion for providing adequate treatment for all patients regardless of where they live.”
Grifols produces plasma-derived medicines to treat rare, chronic diseases such as hemophilia and also develops solutions for the diagnoses of bleeding disorders. The company plans to increase its production of blood clotting factor medicines to specifically meet its donation commitment to this program.
“Since its creation in 1996, the WFH Humanitarian Aid Program has benefitted more than 100,000 people in 90 countries. We are grateful for our contributors’ commitment and support for our mission, such as Grifols, to improve the diagnosis and access to care for people with bleeding disorders who wouldn’t otherwise receive the treatment they need. We have seen time and time again the dramatic positive impact on quality of life that such donations make on patients,” said Alain Bauman , CEO, WFH, and executive director of WFH USA .
An estimated 400,000 people around the world have hemophilia, yet only 25 percent receive adequate treatment. Grifols’ donation also supports the second decade of WFH’s Global Alliance for Progress (GAP) program aimed at increasing the number of patients diagnosed and treated for bleeding disorders, particularly in the world’s most impoverished countries.